Investor Relations

Bio-Thera’s announcement on participating in the 2026 Guangdong Jurisdiction Investor Collective Reception Day and Mid-year Results Briefing for Listed Companies in the Jurisdiction

Bio-Thera’s announcement on convening the STAR Market 2026 Semi-annual Innovative Drug Industry Collective Results Briefing

Bio-Thera’s announcement on the resignation of the Chief Financial Officer and the Chairman and General Manager temporarily performing the duties of the Chief Financial Officer

Bio-Thera’s semi-annual evaluation report on the company’s 2026 special action plan of “Improving Quality, Increasing Efficiency and Focusing on Returns”

Special report on the storage, management and actual use of funds raised by Bio-Thera in the 2026 semi-annual period

Bio-Thera voluntarily discloses the announcement that bevacizumab injection (Pubeixi®) has received a drug supplement application approval notice

Bio-Thera Voluntary Disclosure Regarding Signing with Intas Pharmaceuticals Ltd. for BAT2506 (golimumab) Injection

Voluntary disclosure announcement of Bio-Thera’s 2026 semi-annual performance forecast

Announcement of Bio-Thera’s response to regulatory inquiry letter on information disclosure for 2025 annual report

Bio-Thera’s announcement on EUGMP inspection status of Yonghe factory

Bio-Thera voluntarily discloses the announcement that BAT2206 (ustekinumab injection) has obtained marketing approval from HSA in Singapore

Bio-Thera Announcement on Obtaining Drug Registration Certificate for Aishali®/Xishali® (ustekinumab Injection)

Bio-Thera 2025 Annual Shareholders Meeting Resolution Announcement

Bio-Thera’s announcement that Immgolis™/ImmgolisIntri™ (golimumab injection) has been approved by the US FDA

Bio-Thera Voluntarily Discloses Announcement on Obtaining Drug Clinical Trial Approval Notice for Injectable BAT8013

Announcement of Resolutions of Bio-Thera’s Second Extraordinary Shareholders’ Meeting in 2026

Announcement of Bio-Thera on participating in the 15th Five-Year Plan·Technology Innovation and Benefiting the People - STAR Market Corporate Achievements Transformation and People's Livelihood Empowerment 2025 Pharmaceutical Industry Collective Performance Briefing and the 2026 First Quarter Performance Briefing

Bio-Thera’s announcement on the signing of construction project construction contracts and related transactions between wholly-owned subsidiaries and related parties

Bio-Thera’s announcement regarding its wholly-owned subsidiary’s application for loan business and the company’s guarantee for it

Bio-Thera’s announcement on applying for a credit line from a financial institution

Bio-Thera’s Announcement on Re-appointment of Accounting Firm

Bio-Thera’s announcement regarding the company’s 2026 remuneration package for directors and senior management

Bio-Thera's special report on the storage, management and actual use of the company's 2025 raised funds

Bio-Thera’s announcement on 2025 profit distribution plan

Bio-Thera’s Notice on Convening the 2025 Annual Shareholders Meeting

Announcement of the Resolutions of the Eighth Meeting of the Third Board of Directors of Bio-Thera

Bio-Thera’s announcement on using part of the temporarily idle raised funds and part of its own funds for cash management

Bio-Thera’s announcement on the transfer of rights and interests in drug varieties and related assets and businesses

Bio-Thera’s Notice on Convening the Second Extraordinary Shareholders Meeting in 2026

Bio-Thera voluntarily discloses the notice of clinical trial approval of BAT3306 combined with BAT8008 for the treatment of advanced solid tumors

Bio-Thera Voluntarily Discloses Progress on Receipt of Milestone Payments in Licensing and Commercialization Agreement with STADA for BAT2506 (golimumab) Injection

Bio-Thera voluntarily discloses the notice of drug clinical trial approval for BAT8008 combined with BAT1006 and trastuzumab for the treatment of advanced solid tumors

Bio-Thera voluntarily discloses the announcement that Usymro (ustekinumab injection) has received marketing approval from the UK MHRA

Bio-Thera 2025 Annual Results Express Announcement

Bio-Thera Announces Acceptance of the Marketing Authorization Application for BAT4406F Injection

Bio-Thera’s announcement that Gotenfia (golimumab injection) has received marketing approval from the European EMA

Announcement of Resolutions of Bio-Thera’s First Extraordinary Shareholders Meeting in 2026

Bio-Thera voluntarily discloses announcement regarding the signing of a licensing and production, supply and commercialization agreement with AvalonPharma for BAT3306 (pembrolizumab) injection

Bio-Thera’s announcement on changing the sponsor representative

Bio-Thera 2025 Annual Performance Pre-Loss Announcement

Bio-Thera’s announcement on the return of funds raised to temporarily supplement working capital

Bio-Thera’s Notice on Convening the First Extraordinary Shareholders Meeting in 2026

Bio-Thera Announces Signing of Construction Contracts and Related Transactions between Wholly-Owned Subsidiaries and Related Parties

Bio-Thera voluntarily discloses the progress announcement on the receipt of milestone payments for the licensing and production, supply and commercialization agreement with Gedeon Richter Plc. (Gedeon Richter Plc.) for BAT2206 (ustekinumab) injection

Bio-Thera Voluntarily Discloses Announcement on the Receipt of Milestone Payments from the Licensing and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (ustekinumab) Injection

Bio-Thera voluntarily discloses the progress of receipt of milestone payments in the licensing and commercialization agreement with Sandoz AG for BAT1706 (bevacizumab) injection

Bio-Thera’s announcement on changing the project quality control reviewer

Bio-Thera’s announcement on the company’s expected daily related transactions in 2026

Bio-Thera’s announcement on receiving government subsidies

Bio-Thera’s announcement on acceptance of the marketing authorization application for vericitatumab injection (BAT5906)

Bio-Thera voluntarily discloses the announcement that Gotenfia (golimumab injection) has received a positive opinion from the EMA Committee for Medicinal Products for Human Use

Bio-Thera’s announcement on convening the 2025 third-quarter results briefing

Bio-Thera voluntarily discloses progress on receipt of the upfront payment under the licensing and commercialization agreement with STADA for BAT1806 (tocilizumab) injection

Bio-Thera’s announcement on the departure of a key technical personnel

Announcement of Bio-Thera on Completing the Registration of Industrial and Commercial Change of Registered Address and Amending the Articles of Association of the Company

Bio-Thera Voluntary Disclosure Progress Announcement Regarding Upfront Payment Received with STADA for Signing Licensing and Commercialization Agreement for BAT1806 (tocilizumab) Injection

Bio-Thera Announcement Regarding the Resignation of Core Technicians

Bio-Thera Announces Second Extraordinary General Meeting Resolutions for 2025

Bio-Thera Announces Participation in the 2025 Online Collective Reception Day for Investors in Guangdong Jurisdiction

Bio-Thera voluntarily discloses information about its relationship with IntasPharmaceuticals Ltd. Progress Announcement Receiving Milestone Payment for Signing Licensing and Commercialization Agreement for BAT2506 (Golimumab) Injection

Bio-Thera Voluntary Disclosure Announcement Regarding Marketing Approval of Qletli (Adalimumab Injection) for UK MHRA

Announcement of Bio-Thera on Holding the 2025 Semi-Annual Scientific and Technological Innovation Board Innovation Pharmaceutical Industry Collective Performance Briefing Meeting

Bio-Thera Notice Concerning the Convening of the Second Extraordinary General Meeting in 2025

Bio-Thera Announces Signing of Licensing and Commercialization Agreement with STADA for BAT1806 (tocilizumab) Injection

Bio-Thera Voluntary Disclosure Progress Announcement on Adjustment of BAT3306 (pembrolizumab) Development Strategy

Bio-Thera Announces Market Approval of Usymro (Ursinumab Injection) for European EMA

Bio-Thera Announces Temporary Replenishment of Working Capital with Partially Idle Raised Funds

Special report on the storage, management and actual use of funds raised by Biotec in the semi-annual period of 2025

Bio-Thera's Semi-Annual Evaluation Report on the Company's Special Action Plan for Quality Improvement, Efficiency and Return in 2025

Announcement of Bio-Thera on Revising and Developing Part of the Corporate Governance System

Announcement of Bio-Thera on Changing the Registered Address, Amending the Articles of Association and Registering the Change of Industry and Commerce

Announcement of the results of the reduction of shares held by Bio-Thera shareholders

Bio-Thera Announces Return of Idle Raised Funds Temporarily Used to Replenish Liquidity

Bio-Thera Voluntary Disclosure Regarding BAT1308 Injection Combined with BAT4706 Injection and BAT8008 for Injection for the Treatment of Advanced Solid Tumors

Bio-Thera Voluntarily Discloses Notice of Approval of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (BAT5906) for Drug Clinical Trials

Bio-Thera Announces Change of Office Address and Investor Contact Information

Voluntary Disclosure Announcement of Bio-Thera's Semi-Annual Results Forecast for 2025

Bio-Thera Voluntary Disclosure of Notice of Approval of BAT4406F Injection for Clinical Trials

Bio-Thera Voluntary Disclosure Announcement Regarding Application for Marketing Authorization of BAT2506 (Golimumab) Injection Accepted by FDA in the United States

Bio-Thera Voluntary Disclosure Announcement Regarding Signing of Licensing and Manufacturing, Supply and Commercialization Agreement with SteinCares for BAT2406 (dipulimumab) Injection

Bio-Thera Voluntary Disclosure Announcement Regarding Usymro (Usuzumab Injection) Receiving Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use

Bio-Thera Announces FDA Approval of BAT2206 (ulinumab) Injection

Biotec Announces Adjustment to BAT3306 (pembrolizumab) Development Strategy

Bio-Thera Announces Completion of Board Re-election and Appointment of Senior Management and Securities Representative, Head of Internal Audit

Announcement of Bio-Thera's 2024 Annual General Meeting Resolutions

Announcement of the Resolutions of the 20th Meeting of the Second Session of the Board of Supervisors of

Announcement of Bio-Thera on Holding the 2024 Science and Technology Innovation Board Collective Performance Briefing Meeting

Bio-Thera Shareholder Shareholding Reduction Plan Announcement

Bio-Thera Voluntary Disclosure of Notice of Approval of Drug Clinical Trial for BAT7111 for Injection

Announcement of Bio-Thera on the Election of Employee Representative Directors of the Third Board of Directors of the Company

Announcement of Bio-Thera on the Election of the Board of Directors of the Company

Bio-Thera Announces Renewal of Accounting Firm

Bio-Thera Announces Application for Credit Line with Financial Institutions

Biotec Announces Compensation Plan for Directors and Senior Managers in 2025

Special Report on the Deposit and Actual Use of Funds Raised by Biotec in 2024

Bio-Thera Announcement on Changes and Amount Adjustments of Subprojects of Partial Fundraising Projects

Announcement of Bio-Thera on the Company's Daily Connected Transaction Forecast for 2025

Bio-Thera Notice Concerning the Convening of the 2024 Annual General Meeting

Announcement of Bio-Thera on Amending the Articles of Association and Part of the Corporate Governance System

Announcement of the Resolutions of the 19th Meeting of the Second Session of the Board of Supervisors of B

Announcement of the Resolutions of the 24th Meeting of the Second Session of the Board of Directors of Bio

Bio-Thera Announces Update on BAT1806 (tocilizumab) Business Development

Bio-Thera voluntarily discloses information about its relationship with Intas Pharmaceuticals Ltd. Progress Announcement on Signing Licensing and Commercialization Agreement for BAT2506 (Golimumab) Injection

Announcement of the Resolutions of the 18th Meeting of the Second Session of the Board of Supervisors of B

Announcement of Bio-Thera on the use of part of the temporarily idle raised funds and part of its own funds for cash management

Announcement of the acceptance of Biotec's application for marketing authorization for Golimumab Injection (BAT2506)

Bio-Thera Announces Resignation of Independent Director Upon Completion of Six-Year Term

Bio-Thera Announcement Regarding Resignation of Directors and Senior Management

Announcement of Bio-Thera on Voluntary Disclosure of the Company's Recertification through High-tech Enterprises

Announcement of Resolutions of Bio-Thera's First Extraordinary General Meeting in 2025

Bio-Thera 2024 Annual Results Update Announcement

Bio-Thera Voluntarily Discloses Notice of Approval of Clinical Trials for BAT1006 for Injection Combined with Trastuzumab and Chemotherapy for Breast Cancer

Notice of Bio-Thera on Convening the First Extraordinary General Meeting in 2025

Biotec's relationship with Intas Pharmaceuticals Ltd. Announcement of License and Commercialization Agreement for BAT2506 (Golimumab) Injection

Bio-Thera Announces Acceptance of Application for Marketing Authorization for Curciusumab Injection (BAT2306)

Announcement of Bio-Thera's Shareholding Reduction Result on the Reduction of Shareholding from Shareholders' Equity Holdings of 5% or More to 5% and the Expiration of the Term of the Reduction Plan

Bio-Thera Voluntary Disclosure Announcement Regarding Application for Marketing Authorization of BAT2506 (Golimumab) Injection Accepted by European EMA

Announcement of the Resolutions of the 17th Meeting of the Second Session of the Board of Supervisors of B

Announcement of Bio-Thera's Signing of Construction Contracts and Related Transactions with Related Parties

Announcement of Bio-Thera's Signing of Decoration Mechanical and Electrical Contracts and Related Transactions with Related Parties

Bio-Thera 2024 Annual Results Pre-Loss Announcement

Bio-Thera Voluntary Disclosure Announcement Regarding Signing of Licensing and Manufacturing, Supply and Commercialization Agreement with SteinCares for BAT2306 (Curciusumab) Injection

Announcement of Resolutions at the 20th Meeting of the Second Session of the Board of Directors of

Bio-Thera Voluntary Disclosure with Gedeon Richter Plc. (Jirui Pharmaceuticals) Progress Announcement on Signing Authorization License and Production, Supply and Commercialization Agreement for BAT2206 (ulinumab) Injection Receiving Down Payment and Milestone Payment

Bio-Thera Announces Third Quarter 2024 Results Briefing

Announcement of Bio-Thera's share reduction plan for shareholders holding more than 5% of the shares

Bio-Thera about working with Gedeon Richter Plc. Announcement of (Jirui Pharmaceuticals) Signing of Licensing and Manufacturing, Supply and Commercialization Agreement for BAT2206 (ulinumab) Injection

Announcement of unreduced shareholding by Bio-Thera shareholders holding more than 5% of the shares at the expiration of the plan period

Bio-Thera Announces Participation in the 2024 Online Collective Reception Day for Investors in Guangdong Jurisdiction

Announcement of Bio-Thera's Participation in the 2024 Semi-Annual Scientific and Technological Innovation Board Pharmaceutical and Biological Products Special Group Performance Briefing

Announcement of Biotec's Voluntary Disclosure of Notification of Approval of Drug Clinical Trials for Diplizumab Injection (BAT2406)

Bio-Thera Voluntary Disclosure of Notice of Approval for BAT8006 Combined with Bevacizumab in Clinical Trials

Special Report on the Deposit and Actual Use of Funds Raised by Biotec in Semi-Annual of 2024

Bio-Thera Announces Temporary Replenishment of Working Capital with Partially Idle Raised Funds

Announcement of the Resolutions of the 15th Meeting of the Second Session of the Board of Supervisors of

Bio-Thera Announces Return of Idle Raised Funds Temporarily Used to Replenish Liquidity

Announcement of Biotec regarding the marketing approval of Avzivi (bevacizumab injection) by the European Commission

Voluntary Disclosure Announcement of Bio-Thera's Semi-Annual Results Forecast for 2024

Bio-Thera Voluntary Disclosure with Hikma Pharmaceuticals USA Inc. Announcement of Milestone Payment Received for Signing Licensing and Commercialization Agreement for BAT2206 (ulinumab) Injection

Bio-Thera Voluntary Disclosure Announcement Regarding Application for Marketing Authorization of BAT2206 (ulinumab) Injection Accepted by US FDA and European EMA

Bio-Thera Announces Acquisition of Drug Registration Certificate for Betavibatin Citrate Injection (Betanin)

Bio-Thera Voluntary Disclosure Progress Announcement Regarding Upfront Payment Received with STADA for BAT2506 (Golimumab) Injection Licensing and Commercialization Agreement

Announcement of Biotec regarding the marketing approval of TOFIDENCE (tocilizumab injection) by the European Commission

Announcement from Bio-Thera on Receiving Government Grants

Announcement of Bio-Thera's shareholding reduction plan for shareholders holding more than 5% of the shares

Bio-Thera Voluntary Disclosure Announcement Regarding Avzivi (Bevacizumab Injection) Receiving Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use

Bio-Thera Announces License and Commercialization Agreement with STADA for BAT2506 (Golimumab) Injection

Bio-Thera Voluntary Disclosure Announcement Regarding BAT8008 Combined with Bevacizumab or Combined with BAT7104 to Obtain Notification of Approval for Clinical Trials

Bio-Thera Voluntary Disclosure of Notification of Approval for Clinical Trial of BAT6005 Combined with BAT1308 Injection

Bio-Thera Voluntary Disclosure Announcement Regarding BAT1308 Combined with BAT8006 to Obtain Notification of Approval for Clinical Trials

Bio-Thera Announces Acceptance of Application for Marketing Authorization of BAT2206 (ulinumab) Injection

Bio-Thera Voluntary Disclosure Announcement Regarding TOFIDENCE (tocilizumab Injection) Receiving Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use

Announcement of Bio-Thera's 2023 Annual General Meeting Resolutions

Bio-Thera Voluntary Disclosure Announcement Regarding Acquisition of Drug Registration Certificate for tocilizumab Injection (Schirelli)

Announcement of Bio-Thera's Participation in the 2023 Biological Products Special Group Performance Briefing

Announcement of the signing of the Distributed Rooftop Photovoltaic Power Plant Energy Management Agreement and Connected Transaction between Bio-Thera and Related Parties

Bio-Thera Announcement on Requesting the Board of Directors to Authorize the Issuance of Shares to Specific Targets by Simplified Procedure at the General Meeting of Shareholders

Bio-Thera Announces Appointment of Securities Representative

Bio-Thera Announces Renewal of Accounting Firm

Bio-Thera Announces Application for Credit Line with Financial Institutions

Bio-Thera Announces Compensation Plan for Directors, Supervisors and Senior Executives in 2024

Announcement of Bio-Thera on the use of part of the temporarily idle raised funds and part of its own funds for cash management

Special Report on the Deposit and Actual Use of Funds Raised by Biotec in 2023

Announcement of Bio-Thera on the Company's Daily Connected Transaction Forecast for 2024

Bio-Thera Notice Concerning the Convening of the 2023 Annual General Meeting

Announcement of the Resolutions of the 13th Meeting of the Second Session of the Board of Supervisors of

Announcement of the Resolutions of the 14th Meeting of the Second Board of Directors of Bio

Bio-Thera Voluntary Disclosure Announcement Regarding FDA Approval of Phase II Clinical Trial Application for BAT8006 for Injection

Bio-Thera Voluntarily Discloses Announcement Regarding the Signing of Licensing and Commercialization Agreements with SteinCares for Two Biosimilars Under Development

Bio-Thera Voluntary Disclosure Announcement Regarding BAT8008 Combined with BAT1308 to Obtain Notification of Approval for Drug Clinical Trial

Bio-Thera Voluntary Disclosure of Notice of Approval for Drug Clinical Trials for BAT7205 for Injection

Bio-Thera Voluntary Disclosure of Notification of Approval for Drug Clinical Trial for BAT8010 for Injection in Combination with BAT1006 for Injection

Announcement of the expiration of the plan period for the reduction of the shareholding of Bio-Thera's shareholdings of more than 5% and the results of the reduction

Bio-Thera 2023 Annual Results Update Announcement

Bio-Thera Announces Resignation of Securities Representative

Bio-Thera 2023 Annual Results Pre-Loss Announcement

Bio-Thera Voluntarily Discloses Notice of Clinical Trial Approval for BAT7104 Injection Combined with BAT4706 Injection for Advanced Malignancy

Announcement of Bio-Thera on the Progress of Changes in Shareholders' Equity of the Company and the Completion of Securities Transfer Registration

Bio-Thera Voluntarily Discloses Notice of Clinical Trial Approval for BAT1308 Injection in Combination with Platinum-Containing Chemotherapy for Endometrial Cancer

Biotec Announces FDA Approval of BAT1706 (Bevacizumab) Injection

Bio-Thera's Indicative Announcement on Changes in Shareholders' Equity of More than 5%

Announcement of the Resolutions of the 12th Meeting of the Second Session of the Board of Supervisors of

Announcement of Resolutions at the 13th Meeting of the Second Session of the Board of Directors of

Announcement of Bio-Thera on Diluted Immediate Returns of A Shares Issued to Specific Targets and the Company's Adjustment Measures and Related Subject Commitments (Revised Draft)

Bio-Thera Announces Amendment to Proposal to Issue A Shares to Specific Targets in 2023

Bio-Thera's Proposed (Revised) Disclosure of A-Shares to Specific Targets in 2023

Bio-Thera Announces Third Quarter 2023 Results Briefing

Announcement of Resolutions of Bio-Thera's First Extraordinary General Meeting in 2023

Biotec Announces FDA Approval of BAT1806 (tocilizumab) Injection

Bio-Thera's Indicative Announcement on Changes in the Percentage of Equity of Shareholders with a Shareholding of 5% or More and Their Concerted Actions Exceeding 1%

Announcement of the signing of the Distributed Rooftop Photovoltaic Power Plant Energy Management Agreement and Connected Transaction between Bio-Thera and Related Parties

Notice of Bio-Thera on Convening the First Extraordinary General Meeting in 2023

Announcement of the Resolutions of the Tenth Meeting of the Second Session of the Board of Supervisors of

Bio-Thera Announces Participation in the Online Group Reception Day for Investors of Listed Companies in Guangdong Jurisdiction in 2023

Bio-Thera Announces Change of Sponsor Representative

Announcement of Biotec on Early Termination of Shareholding Reduction Scheme by Concerted Actions of Controlling Shareholders

Announcement of Bio-Thera's Participation in the Semiannual Pharmaceutical and Biological Products Industry Collective Performance Briefing 2023

Announcement of Bio-Thera on the Application for the Issuance of a Guarantee and the Provision of a Pledge Guarantee

Bio-Thera Announces Application for Comprehensive Credit Line with Financial Institutions

Special report on the use of funds raised by Bio-Thera as of June 30, 2023

Announcement of the Resolutions of the Ninth Meeting of the Second Session of the Board of Supervisors of

Bio-Thera Announces Temporary Replenishment of Working Capital with Partially Idle Raised Funds

Bio-Thera's Special Report on the Deposit and Actual Use of Funds Raised in Semi-Annual of 2023

Bio-Thera Announces Return of Idle Raised Funds Temporarily Used to Replenish Liquidity

Announcement of Bio-Thera's share reduction plan for shareholders holding more than 5% of the shares

Voluntary Disclosure Announcement of Bio-Thera's Semi-Annual Results Forecast for 2023

Bio-Thera Voluntarily Discloses Notice of Clinical Trial Approval for BAT4706 Injection Combined with BAT1308 Injection for Advanced Solid Tumors

Announcement of the expiration of the plan period for the reduction of the shareholding of Bio-Thera's shareholdings of more than 5% and the results of the reduction

Announcement of the Resolutions of the Eighth Meeting of the Second Session of the Board of Supervisors of

Announcement of Resolutions at the Ninth Meeting of the Second Board of Directors of BioT

Announcement of Bio-Thera on Diluted Immediate Returns of A Shares Issued to Specific Targets and the Company's Adjustment Measures and Related Subject Commitments (Revised Draft)

Bio-Thera Announces Amendment to Proposal to Issue A Shares to Specific Targets in 2023

Bio-Thera's Proposed (Revised) Disclosure of A-Shares to Specific Targets in 2023

Announcement by Bio-Thera on Adjusting the Company's Plan to Issue A-Shares to Specific Targets in 2023

Bio-Thera Voluntarily Discloses Notice of Approval of Clinical Trial for BAT1308 Injection Combination Therapy for Cervical Cancer

Bio-Thera Voluntary Disclosure of Notification of Approval for Drug Clinical Trial for New Indication for BAT6026 Injection

Announcement of the Resolutions of the Seventh Meeting of the Second Session of the Board of Supervisors of

Announcement of Bio-Thera's Participation in the 2022 Biological Products Special Group Performance Briefing

Bio-Thera's Progress Announcement on the Reduction of Holdings by More Than 5% of Shareholders for More Than Half of

Announcement of Bio-Thera's 2022 Annual General Meeting Resolutions

Announcement of Bio-Thera's Plan to Reduce Shares Held by Consistent Actors of Controlling Shareholders

Announcement of Resolutions at the Seventh Meeting of the Second Session of the Board of Directors of

Bio-Thera Announces Renewal of Accounting Firm

Announcement of Bio-Thera on the use of part of the temporarily idle raised funds for cash management and retroactive use of part of the temporarily idle raised funds for cash management

Bio-Thera Announces Compensation Plan for Directors, Supervisors and Senior Executives in 2023

Announcement of the Resolutions of the Sixth Meeting of the Second Session of the Board of Supervisors of

Special report on the deposit and actual use of funds raised by Bio-Thera in 2022

Bio-Thera Announcement on Changes and Amount Adjustments of Subprojects of Partial Fundraising Projects

Special report on the use of funds raised by Bio-Thera as of March 31, 2023

Announcement of Bio-Thera on the Company's Daily Connected Transaction Forecast for 2023

Bio-Thera Announces 2022 Annual General Meeting

Bio-Thera Announcement Regarding the Commitment of Controlling Shareholders Not to Reduce Their Shares in the Company for a Specific Period

Announcement of Bio-Thera's share reduction plan for shareholders holding more than 5% of the shares

Bio-Thera Announces Application for Mortgage Credit from Financial Institutions

Announcement of Bio-Thera regarding the unavailability of a report on the use of previously raised funds at the time of disclosure of this plan to issue A shares to specific parties

Announcement of Bio-Thera on Penalties or Regulatory Measures Taken by Securities Regulatory Authorities and Exchanges in the Last Five Years

Bio-Thera Announces Diluted Immediate Return on A-Shares Issued to Specific Targets and the Company's Adjustment Measures and Related Subject Commitments

Bio-Thera's Indicative Announcement Regarding the Disclosure of the Proposal to Issue A Shares to Specific Targets in 2023

Announcement of Bio-Thera on Temporarily Not Convening a General Meeting to Consider Matters Related to the Issue of A Shares to Specific Targets

Bio-Thera 2 nd Board of Supervisors 5 th meeting resolutions announcement

Bio-Thera 2 nd Board of Directors 6 th meeting resolutions announcement

Bio-Thera 2022 Annual Results Update Announcement

Announcement on the Listing and Circulation of Some of the Restricted Shares of Bio-Thera's Initial Public Offering

Bio-Thera voluntary disclosure regarding tocilizumab injection (Shiruili)announcement on obtaining a drug registration certificate

Bio-Thera 2022 Announcement of expected annual loss

Bio-Thera Voluntary Disclosure Announcement Regarding the Registration Progress of the Company's tocilizumab Injection (Schriel)

Bio-Thera Voluntary Disclosure Announcement Regarding the Acceptance of BAT1806 (tocilizumab) Injection Application for FDA Marketing Authorization in the United States

Bio-Thera convening 2022 semi-annual and 3 rd quarterly results briefing announcement

Bio-Thera Voluntary Disclosure Announcement Regarding Acceptance of BAT1806 (tocilizumab) Injection Application for Marketing Authorization in Europe EMA

Bio-Thera Announces Notification of Clinical Trial Approval for BAT8007 for Injection

Bio-Thera Announces Notification of Clinical Trial Approval for BAT8008 for Injection

Bio-Thera 2 nd Board of Supervisors 3 rd meeting resolutions announcement

Announcement of Bio-Thera on Applying for Mortgage Credit from Banks

Bio-Thera announcement on temporarily using part of idle proceeds to supplement working capital

Bio-Thera 2022 semi-annual Special report on the deposit and actual use of proceeds

Bio-Thera announcement on returning idle proceeds temporarily used to supplement working capital

Bio-Thera Announcement on the Receipt of the Warning Letter from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission by the Company and Related Personnel

Bio-Thera Announces Receipt of VAT Overdue Tax Refund

Bio-Thera announcement on receiving government grants

Announcement of Voluntary Disclosure of Biotec's 2022 Semi-Annual Results Forecast

Bio-Thera Voluntarily Discloses Notice of Clinical Trial Approval for BAT8010 for Injection

Bio-Thera 2022 1 st interim General Meeting of Shareholders resolutions announcement

Bio-Thera Announces Notification of Clinical Trial Approval for BAT2022 for Injection

Bio-Thera convening 2022 1 st interim General Meeting of Shareholders notice

Bio-Thera 2 nd Board of Supervisors 2 nd meeting resolutions announcement

Announcement of Bio-Thera on Signing Construction Contracts and Related Transactions with Related Parties

Bio-Thera Announces Completion of Change of Legal Representative and Renewal of Business License

Bio-Thera Announces 2021 Annual Performance Briefing

Bio-Thera 2 nd Board of Supervisors 1 st meeting resolutions announcement

Announcement of Bio-Thera on the Completion of the Election of the Board of Directors and the Board of Supervisors and the Appointment of Senior Management and Securities Affairs Representatives

Bio-Thera 2021 Annual General Meeting resolutions announcement

Bio-Thera voluntary disclosure regarding bevacizumab injection (Pubeixi)announcement on receiving a drug supplement application approval notice

Announcement of Bio-Thera on the election of the board of directors and the board of supervisors of the company

Bio-Thera announcement on the change of accounting firm

Bio-Thera Announces Application for Comprehensive Credit Line with Financial Institutions

Bio-Thera Announces 2022 Remuneration Plan for Directors, Supervisors and Senior Executives

Bio-Thera 2021 Special Report on the Deposit and Actual Use of Funds Raised

Bio-Thera Announces Forecast for Daily Connected Transactions in 2022

Bio-Thera convening 2021 Annual General Meeting notice

Announcement of Bio-Thera on the Election of Employee Representatives and Supervisors of the Second Session of the Board of Supervisors

Announcement of the Resolutions of the 23rd Meeting of the First Session of the Board of Supervisors of BioT

Announcement of Bio-Thera on the First Profit and Cancellation of the Stock Abbreviation Special Identification U

Bio-Thera announcement on receiving government grants

Bio-Thera Announces Notification of Clinical Trial Approval for BAT8009 for Injection

Bio-Thera Voluntarily Discloses Announcement Regarding the Company's Accreditation of High-tech Enterprises

Biotec Announces Notification of Clinical Trial Approval for Mapolizumab Injection (BAT2606)

Announcement of the Resolutions of the 22nd Meeting of the First Session of the Board of Supervisors of Bi

Bio-Thera announcement on cash management using part of temporarily idle proceeds and proprietary funds

Announcement on the Listing and Circulation of Some of the Restricted Shares of Bio-Thera's Initial Public Offering

Bio-Thera Announces Notification of Clinical Trial Approval for BAT8006 for Injection

Bio-Thera's Reminder Announcement Regarding the Postponement of the Board of Directors and the Board of Supervisors

Announcement of the expiration of the plan period for the reduction of the shareholding of Bio-Thera's shareholdings of more than 5% and the results of the reduction

Announcement of Bio-Thera's 2021 Annual Results Snapshot

Announcement on the Listing and Circulation of Bio-Thera's Initial Public Offering Strategic Placing of Restricted Shares

Bio-Thera 2021 Annual Results Pre-Profit Announcement

Bio-Thera Announces Progress in Receiving Milestone Payments for Signing Authorization, Distribution, and Supply Agreements for BAT1706 (bevacizumab)

Bio-Thera voluntary disclosure regarding adalimumab injectionannouncement on receiving a drug supplement application approval notice

Bio-Thera's Progress Announcement on the Reduction of Holdings by More Than 5% of Shareholders for More Than Half of

Bio-Thera company bevacizumab injection (Pubeixi®)announcement on obtaining a drug registration certificate

Bio-Thera 2021 2 nd interim General Meeting of Shareholders resolutions announcement

Bio-Thera tocilizumab injection(BAT 1806)announcement on the acceptance of a marketing authorization application

Bio-Thera convening 2021 2 nd interim General Meeting of Shareholders notice

Bio-Thera 1 st Board of Supervisors 20 th meeting resolutions announcement

Announcement of Bio-Thera on Signing Construction Contracts and Related Transactions with Related Parties

Bio-Thera Voluntarily Discloses Notice of Clinical Trial Approval for BAT7104 Injection

Bio-Thera Announcement on Public Bidding Results and Related Transactions

Bio-Thera Announces Completion of Business Scope Change Registration and Amendment to the Articles of Association

PARKnSHOP's Announcement Regarding the Termination of the Company's Issuance of H Shares and their Listing on the Stock Exchange of Hong Kong

Bio-Thera voluntary disclosure regarding adalimumab injectionannouncement on receiving a drug supplement application approval notice

Bio-Thera convening 2021 semi-annual results briefing announcement

Bio-Thera 2021 1 st interim General Meeting of Shareholders resolutions announcement

Bio-Thera bAT 1706 (bevacizumab) injectionannouncement on signing a license and commercialization agreement

Bio-Thera regarding Hikma Pharmaceuticals USA Inc. for BAT 2206 (ustekinumab) injectionannouncement on signing a license and commercialization agreement

Bio-Thera convening 2021 1 st interim General Meeting of Shareholders notice

Bio-Thera 1 st Board of Supervisors 19 th meeting resolutions announcement

Bio-Thera Announces Resignation of Independent Non-Executive Director

Bio-Thera Announcement on Changes and Amount Adjustments of Subprojects of Partial Fundraising Projects

Announcement of Biotec on Changing the Scope of Business, Amending the Articles of Association and Registering Changes in Industry and Commerce

Bio-Thera Announces Application for Comprehensive Credit Line with Financial Institutions

Bio-Thera announcement on temporarily using part of idle proceeds to supplement working capital

Bio-Thera 2021 semi-annual Special report on the deposit and actual use of proceeds

Bio-Thera announcement on returning idle proceeds temporarily used to supplement working capital

Announcement of Bio-Thera's share reduction plan for shareholders holding more than 5% of the shares

Bio-Thera 2021 Voluntary disclosure of the semi-annual earnings forecast

Bio-Thera regarding Biogen for BAT 1806 (tocilizumab) injectionprogress announcement on receiving an upfront payment under the license and commercialization agreement

Bio-Thera Voluntarily Discloses Notice of Clinical Trial Approval for BAT6005 Injection

Bio-Thera Voluntarily Discloses Notice of Clinical Trial Approval for BAT6021 Injection

Bio-Thera Voluntary Disclosure of Notification of Clinical Trial Approval for Subcutaneous tocilizumab Injection (BAT1806)

Bio-Thera Voluntarily Discloses Notice of Clinical Trial Approval for BAT6026 Injection

Bio-Thera Voluntary Disclosure of Notice of Clinical Trial Approval for BAT4706 Injection

Bio-Thera regarding Biogen for BAT 1806 (tocilizumab) injectionannouncement on signing a license and commercialization agreement

Bio-Thera 2020 Annual General Meeting resolutions announcement

Announcement of Bio-Thera on Resubmitting the Application for Listing of Overseas Listed Foreign Shares (H Shares) and Issuing the Application Materials to the Hong Kong Stock Exchange

Bio-Thera voluntary disclosure regarding adalimumab injection announcement on receiving a drug supplement application approval notice

Bio-Thera Announces Termination of BAT8003 and BAT1306 Clinical Trials

Bio-Thera 1 st Board of Supervisors 17 th meeting resolutions announcement

Bio-Thera convening 2020 Annual General Meetingnotice

Bio-Thera Announces Renewal of Accounting Firm of the Year 2021

Bio-Thera announcement on appointing senior management

Bio-Thera announcement on cash management using part of temporarily idle proceeds

Special Report on the Deposit and Actual Use of Funds Raised by Biotec in 2020

Bio-Thera Announces Remuneration Plan for Directors, Supervisors and Senior Executives for 2021

Bio-Thera special assurance report on non-operating fund occupation

Bio-Thera 2020 annual audit report

Bio-Thera Announces Changes to Employee Supervisors

Bio-Thera 2020 Annual Results Update Announcement

Bio-Thera voluntary disclosure regarding adalimumab injectionannouncement on receiving a drug supplement application approval notice

Bio-Thera Announces Discontinuation of BAT8001 Clinical Trial

Bio-Thera Voluntary Disclosure of an Indicative Announcement Regarding the Progress of the BAT8001 Clinical Trial

Bio-Thera Voluntary Disclosure of Notification of Clinical Trial Approval for Curcitumumab (BAT2306) Injection

Announcement on the Listing and Circulation of Some of the Restricted Shares of Bio-Thera's Initial Public Offering

Bio-Thera Correction Announcement on 2020 Annual Results Forecast Loss

Bio-Thera 2020 Announcement of expected annual loss

Bio-Thera Voluntary Disclosure Announcement Regarding Acceptance of Application for Marketing Authorization of Bevacizumab Injection (BAT1706) in the United States FDA

Bio-Thera receiving invention patent voluntary disclosure announcement

Bio-Thera announcement on the change of sponsor representative

Announcement of Bio-Thera on the Approval of the China Securities Regulatory Commission for the Initial Public Offering of Overseas Listed Foreign Shares

Bio-Thera bAT 1006 injectionannouncement on receiving a clinical trial notice

Bio-Thera Announces Progress in Receiving Down Payment for Signing Authorization, Distribution, and Supply Agreement with Baiji Shenzhou Co., Ltd. for BAT1706 (Bevacizumab)

Bio-Thera announcement on temporarily using part of idle proceeds to supplement working capital

Bio-Thera Announces Acceptance of Application for Marketing Authorization of Batifiban Injection (BAT2094)

Bio-Thera 1 st Board of Supervisors 15 th meeting resolutions announcement

Bio-Thera announcement on receiving government grants

Announcement of Resolutions of Bio-Thera's Third Extraordinary General Meeting in 2020

Bio-Thera convening 2020 3 rd interim General Meeting of Shareholders notice

Bio-Thera 1 st Board of Supervisors 14 th meeting resolutions announcement

Bio-Thera 2020 semi-annual Special report on the deposit and actual use of proceeds

Bio-Thera Announces the Signing of an Authorization, Distribution and Supply Agreement with Baiji Shenzhou Co., Ltd. for BAT1706 (bevacizumab)

Bio-Thera's Supplemental Announcement on Financial Data for the First Quarter of 2020

Announcement of Bio-Thera on Submitting an Application for Listing of Overseas Listed Foreign Shares (H Shares) and Issuing Application Materials to the Hong Kong Stock Exchange

PARKnSHOP's Announcement on the Disclosure of Partial Financial Data for the 2020 Half-Year on the Hong Kong Stock Exchange

Announcement on the Listing and Circulation of Bio-Thera's Offline Placing of Restricted Shares for Initial Public Offering

Announcement of Bio-Thera's Application for Issuance of Overseas Listed Foreign Shares (H Shares) Accepted by the China Securities Regulatory Commission

Announcement of Biotec on Obtaining Adalimumab Injection "Notice of Approval of Drug Supplement Application"

Announcement of Biotec on the Selection of Candidates for Independent Non-Executive Directors of the Company

Bio-Thera Announces Application for Comprehensive Credit Line with Financial Institutions

Bio-Thera 2020 2 nd interim General Meeting of Shareholders resolutions announcement

Announcement of Biotec on Obtaining Adalimumab Injection "Notice of Approval of Drug Supplement Application"

Bio-Thera Announces Amendment to the Articles of Association (Draft) Applicable to the Listing of H Shares

Bio-Thera convening 2020 2 nd interim General Meeting of Shareholders notice

Announcement of Biotec on the Selection of Candidates for Independent Non-Executive Directors of the Company

Bio-Thera 1 st Board of Supervisors 13 th meeting resolutions announcement

Bio-Thera 1 st Board of Directors 17 th meeting resolutions announcement

Bio-Thera Announces Purchase of Directors' Liability Insurance

Bio-Thera announcement on the change of accounting firm

Bio-Thera bevacizumab injection(BAT 1706)announcement on the acceptance of a marketing authorization application

Bio-Thera 1 st Board of Supervisors 12 th meeting resolutions announcement

Bio-Thera 1 st Board of Directors 16 th meeting resolutions announcement

Bio-Thera's Indicative Announcement on Matters Relating to the Company's Plan to Issue H Shares and List them in Hong Kong

Bio-Thera bAT 1308 injectionannouncement on receiving a clinical trial notice

Announcement of Resolutions at Biotec's 2019 Annual General Meeting

Bio-Thera Announces 2019 Annual Performance Briefing

Bio-Thera 2019 Annual General Meeting Information

Bio-Thera announcement on obtaining an invention patent

Bio-Thera special assurance report on non-operating fund occupation

Bio-Thera 2019 annual audit report

Bio-Thera 1 st Board of Supervisors 11 th meeting resolutions announcement

Notice of Bio-Thera Convening the 2019 Annual General Meeting

Bio-Thera announcement on appointing the securities affairs representative

Bio-Thera announcement on changing registered capital and company type, amending the Articles of Association and completing industrial and commercial registration

Bio-Thera announcement on the change of accounting firm

Bio-Thera 2020 annual announcement on the remuneration plan for directors, supervisors and senior management

Bio-Thera announcement on appointing senior management

Bio-Thera announcement on receiving government grants

Bio-Thera announcement on cash management using part of temporarily idle proceeds

Bio-Thera announcement on using proceeds to replace self-raised funds previously invested in fundraising projects

Bio-Thera 1 st Board of Supervisors 10 th meeting announcement

Bio-Thera recombinant anti-VEGFhumanized monoclonal antibody injectionannouncement on receiving a clinical trial notice

Announcement of Bio-Thera's 2019 Annual Results Update